MediciNova, Inc.,has announced a modification to its contract with the Biomedical Advanced Research and Development Authority (BARDA), a part of the Administration for Strategic Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services, to
Emergent BioSolutions Inc. (NYSE:EBS) announced today a research award by the U.S. Department of Defense (DoD) Congressionally Directed Medical Research Programs (CDMRP) to evaluate
Rafa Laboratories LTD. ("Rafa") is pleased to announce the U.S. Food and Drug Administration has approved its "first in market" 10 mg midazolam autoinjector for the treatment of status epilepticus in adults.
Swiss biotech Fastox Pharma will present for the first time its groundbreaking long-lasting botulinum toxin LAST technology at the leading conference on neurotoxins from July 27thto July 30th in New Orleans, USA.
Fastox has discovered that combining botulinum toxin type A (BoNT/A) with
Chimerix, a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announces it has entered into a definitive agreement with Emergent BioSolutions Inc. (Emergent) to acquire its exclusive
SIGA Technologies, Inc. (SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the U.S. Food and Drug Administration (FDA) approved the intravenous (IV) formulation of TPOXX for the treatment of smallpox. The IV formulation is an important
The U.S. Department of Defense (DOD) awarded Dynavax Technologies Corporation with an agreement worth approximately $22 million over two and a half years, to execute a clinical trial combining the DOD’s recombinant plague (rF1V) vaccine with its own CpG 1018® adjuvant. Under the agreement,
MediciNova, Inc., a biopharmaceutical company, today announced it has partnered with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and
Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that Health Canada has expanded the approval of the Company’s non-replicating smallpox vaccine, IMVAMUNE® to include additional indications – specifically, monkeypox and related orthopoxvirus infections and disease in
BARDA is partnering with Invirsato develop the company’s investigational product INV-102 to treat ocular conditions associated with DNA damage to include sulfur mustard injury. By funding this advanced research and development
On October 14 the U.S. Food and Drug Administration approved Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn), a mixture of three monoclonal antibodies, as the first FDA-approved treatment for Zaire ebolavirus (Ebola virus) infection in adult and pediatric
SRI International has been awarded a contract of up to from the National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to support the research and development of radiation/nuclear medical countermeasures (MCMs). Under the contract, SRI
PharmaJet, the maker of innovative, needle-free injection technology, announced that it received a $9.6 million dollar contract award from the Joint Science and Technology Office of the U.S. Defense Threat Reduction Agency
Inovio Pharmaceuticals, USA has announced the Coalition for Epidemic Preparedness Innovations (CEPI) has awarded Inovio a grant of up to $9 million to develop a vaccine against the recently emerged strain of coronavirus (2019-nCoV). This initial CEPI funding will support Inovio's
The University of Minnesota Twin Cities and Windgap Medical have received a $3.2 million grant from the National Institutes of Health (NIH) to develop a new device to quickly administer a recently developed antidote for cyanide poisoning.
MediWound Ltd. and its U.S. commercial partner Vericel Corporation have announced that BARDA has begun procuring NexoBrid for emergency stockpile as part of the HHS mission to build national preparedness for public